Investigation of SCGB3A1 (UGRP2) Gene Arrays in Patients with Nasal Polyposis

dc.contributor.authorPalali, Mehmet
dc.contributor.authorOzcan, K. Murat
dc.contributor.authorOzdas, Sibel
dc.contributor.authorKoseoglu, Sabri
dc.contributor.authorOzdas, Talih
dc.contributor.authorErbek, Selim S.
dc.contributor.authorYildirim, Erol
dc.contributor.authorEnsari, Serdar
dc.contributor.authorDere, Huseyin
dc.contributor.orcIDhttps://orcid.org/0000-0003-4825-3499en_US
dc.contributor.pubmedID24710847en_US
dc.contributor.researcherIDB-7604-2019en_US
dc.date.accessioned2023-12-14T12:42:20Z
dc.date.available2023-12-14T12:42:20Z
dc.date.issued2014
dc.description.abstractThe aim of the current study is to investigate the potential relationship between polymorphisms and nasal polyposis (NP) pathogenesis in the SCGB3A1 (UGRP2) gene, which is a member of the secretoglobin gene super family. Genotypic variations were studied by performing DNA sequencing in blood samples of 80 patients with NP and 70 healthy individuals to evaluate nucleotide changes and their positions that might be in the SCGB3A1 gene (promotor, splicing points, and exon distributions). In the SCGB3A1 gene, three single-nucleotide changes labeled IVS1-89 T > G, c. -183 G > T, IVS1-189 G > A were identified. IVS1-89 T > G and IVS1-189 G > A belong to the first intronic region of the gene, whereas c. -183 G > T was observed in the promoter region of the gene. The IVS1-89 T > G nucleotide change was observed in the patient and control groups, whereas c. -183 G > T and IVS1-189 G > A nucleotide changes were observed in the control group only. SCGB3A1 (IVS1-89) genotype frequencies between patients with NP and control group were not significantly different (p = 0.311). There was a statistically significant difference in the control group in comparison to patients with NP in terms of SCGB3A1 (c. -183 GT) and SCGB3A1 (IVS1-189 GA) frequency (p = 0.0045 and p = 0.009, respectively). The findings of the current study suggest that SCGB3A1-183 T and SCGB3A1 IVS1-189 A alleles might have a protective effect against NP, and that SCGB3A1 (-183 GT and IVS1-189 GA) genotypes should be studied in future population-based studies.en_US
dc.identifier.endpage3214en_US
dc.identifier.issn0937-4477en_US
dc.identifier.issue12en_US
dc.identifier.scopus2-s2.0-84897358300en_US
dc.identifier.startpage3209en_US
dc.identifier.urihttp://hdl.handle.net/11727/11108
dc.identifier.volume271en_US
dc.identifier.wos000344773400015en_US
dc.language.isoengen_US
dc.relation.isversionof10.1007/s00405-014-3020-8en_US
dc.relation.journalEUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNasal polyposisen_US
dc.subjectSingle-nucleotide polymorphismen_US
dc.subjectSecretoglobinsen_US
dc.subjectSCGB3A1en_US
dc.subjectDNA sequence analysisen_US
dc.subjectChronic inflammationen_US
dc.subjectPathogenesisen_US
dc.titleInvestigation of SCGB3A1 (UGRP2) Gene Arrays in Patients with Nasal Polyposisen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: